This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
zacks-consensus-estimate: Archive
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -22.73% and +5.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TLSIPositive Net Change MDTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
STOKPositive Net Change MRSNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of +50.00% and +75.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LCTXPositive Net Change BFRINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CUEPositive Net Change FENCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
York Water (YORW) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
York Water (YORW) delivered earnings and revenue surprises of +6.06% and +1.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
YORWPositive Net Change GWRSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -3.85% and -0.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
RPIDNegative Net Change LUCDPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sotherly Hotels (SOHO) Lags Q2 FFO and Revenue Estimates
by Zacks Equity Research
Sotherly Hotels (SOHO) delivered FFO and revenue surprises of -38.24% and -5.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SOHONegative Net Change AFCGNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TCRXNegative Net Change EDITPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TSHANo Net Change PINCPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -13.95% and +124.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
LQDANegative Net Change KMDANo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Madison Square Garden (MSGS) Reports Q4 Loss, Beats Revenue Estimates
by Zacks Equity Research
Madison Square Garden (MSGS) delivered earnings and revenue surprises of +83.33% and +23.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MSGSPositive Net Change LUCKPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +1.96% and +16.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
OBIONegative Net Change GBIONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Ondas Holdings Inc. (ONDS) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Ondas (ONDS) delivered earnings and revenue surprises of +27.27% and +11.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ONDSNegative Net Change AINegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Paysafe Limited (PSFE) Meets Q2 Earnings Estimates
by Zacks Equity Research
Paysafe Limited (PSFE) delivered earnings and revenue surprises of 0.00% and +0.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PSFENegative Net Change CTLPPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Coya Therapeutics, Inc. (COYA) delivered earnings and revenue surprises of -63.64% and -96.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
COYAPositive Net Change CVACNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
DarioHealth (DRIO) delivered earnings and revenue surprises of -9.09% and -22.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DRIOPositive Net Change HYPRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Eagle Point (ECC) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Eagle Point (ECC) delivered earnings and revenue surprises of -8.00% and -5.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ECCPositive Net Change BFINNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Hydrofarm Holdings Group, Inc. (HYFM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Hydrofarm (HYFM) delivered earnings and revenue surprises of -51.88% and -6.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
HYFMPositive Net Change LODEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
IHS Holding (IHS) Lags Q2 Earnings Estimates
by Zacks Equity Research
IHS Holding (IHS) delivered earnings and revenue surprises of -41.18% and +1.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
IHSPositive Net Change ADSKPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BTAIPositive Net Change CDXSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Bitcoin Depot Inc. (BTM) Misses Q2 Earnings Estimates
by Zacks Equity Research
Bitcoin Depot Inc. (BTM) delivered earnings and revenue surprises of -5.88% and +1.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BTMNegative Net Change XPPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Broadwind Energy, Inc. (BWEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Broadwind Energy (BWEN) delivered earnings and revenue surprises of -300.00% and +3.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BWENNegative Net Change NDSNNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Cardinal Health (CAH) Tops Q4 Earnings Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of +2.46% and -0.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CAHNegative Net Change PDEXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ACCESS Newswire Inc. (ACCS) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ACCESS Newswire Inc. (ACCS) delivered earnings and revenue surprises of -6.67% and -4.08%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ACCSNegative Net Change MSGEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -38.89% and +0.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ADCTNegative Net Change ALVONegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank